Prostate Cancer
Effect of PSMA PET/CT on the Use of Bone Scintigraphy for Prostate Cancer at a University Hospital System.
September 9, 2024
Impact of TP53 loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients.
September 9, 2024
Development of prediction models based on risk scores for clinically significant prostate cancer on MRI/TRUS fusion biopsy.
September 6, 2024
PARP Inhibitor Addition to Androgen Receptor Pathway Inhibitors in Metastatic Castration-resistant Prostate Cancer Should Be Limited to BRCA Mutation Carriers.
September 6, 2024
The Use of Lurbinectedin for the Treatment of Small Cell and Neuroendocrine Carcinoma of the Prostate.
September 6, 2024
Comparison of Pathologist and Artificial Intelligence-based Grading for Prediction of Metastatic Outcomes After Radical Prostatectomy.
September 6, 2024
Talazoparib for the treatment of prostate cancer.
September 5, 2024
PSMA PET improves characterization of dural-based intracranial lesions in patients with metastatic prostate cancer.
September 5, 2024
Pelvic Lymph Node Dissection: A Comparison Among Extraperitoneal Single-port and Transperitoneal Multiport Radical Prostatectomy-A Single-center Experience.
September 5, 2024
The Man Van: A pilot study of using mobile targeted case-finding to address health inequalities in prostate cancer.
September 5, 2024
The Proteogenomics of Prostate Cancer Radioresistance.
September 5, 2024
Local salvage therapies in patients with radio-recurrent prostate cancer following external beam radiotherapy: a systematic review and meta-analysis.
September 4, 2024
Androgen production, uptake, and conversion (APUC) genes define prostate cancer patients with distinct clinical outcomes.
September 4, 2024
Statin concentration in prostatic tissue is subtype- and dose-dependent.
September 4, 2024